Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Incidence of Toxoplasma retinochoroiditis in patients with ankylosing spondylitis after using TNF-α blockers.

Rodrigues KF, Faria e Arantes TE, Muccioli C, Neto JL, Pinheiro MM.

Parasitol Int. 2013 Jun;62(3):272-5. doi: 10.1016/j.parint.2013.02.003. Epub 2013 Feb 26.

PMID:
23485566
2.

Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.

Suh YS, Kwok SK, Ju JH, Park KS, Park SH, Yoon CH.

J Korean Med Sci. 2014 Jan;29(1):38-42. doi: 10.3346/jkms.2014.29.1.38. Epub 2013 Dec 26. Erratum in: J Korean Med Sci. 2014 Mar;29(3):460.

3.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

4.

Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers.

Kim EM, Uhm WS, Bae SC, Yoo DH, Kim TH.

J Rheumatol. 2011 Oct;38(10):2218-23. doi: 10.3899/jrheum.110373. Epub 2011 Aug 15.

PMID:
21844149
5.

[Anti-TNF alfa therapy in ankylosing spondylitis].

Cravo AR, Tavares V, Da Silva JC.

Acta Med Port. 2006 Mar-Apr;19(2):141-50. Epub 2006 Aug 18. Review. Portuguese.

6.

TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment.

Micu MC, Micu R, Surd S, Gîrlovanu M, Bolboacă SD, Ostensen M.

Rheumatology (Oxford). 2014 Jul;53(7):1250-5. doi: 10.1093/rheumatology/keu007. Epub 2014 Mar 5.

PMID:
24599921
7.

Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.

Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, Emery P, Marzo-Ortega H.

Rheumatology (Oxford). 2008 Jun;47(6):897-900. doi: 10.1093/rheumatology/ken094. Epub 2008 Apr 10.

PMID:
18403400
8.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

9.

Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation.

Pedersen SJ, Chiowchanwisawakit P, Lambert RG, Østergaard M, Maksymowych WP.

J Rheumatol. 2011 Jul;38(7):1349-54. doi: 10.3899/jrheum.100925. Epub 2011 Apr 1.

PMID:
21459937
10.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.

Ann Rheum Dis. 2004 Jun;63(6):665-70. Epub 2004 Mar 22.

11.

Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.

Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, Dernis E, Wendling D, Ansemant T, Berthelot JM, Bader-Meunier B, Kantelip B; Le CRI.

Joint Bone Spine. 2012 Oct;79(5):457-63. doi: 10.1016/j.jbspin.2011.10.001. Epub 2011 Nov 15.

PMID:
22088934
12.

Toxoplasmic Retinochoroiditis: Clinical Characteristics and Visual Outcome in a Prospective Study.

Aleixo AL, Curi AL, Benchimol EI, Amendoeira MR.

PLoS Negl Trop Dis. 2016 May 2;10(5):e0004685. doi: 10.1371/journal.pntd.0004685. eCollection 2016 May.

13.

Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis.

van Sijl AM, van Eijk IC, Peters MJ, Serné EH, van der Horst-Bruinsma IE, Smulders YM, Nurmohamed MT.

Ann Rheum Dis. 2015 Jan;74(1):119-23. doi: 10.1136/annrheumdis-2013-203934. Epub 2013 Oct 3.

PMID:
24092419
14.

The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.

Kang KY, Lee KY, Kwok SK, Ju JH, Park KS, Hong YS, Kim HY, Park SH.

Joint Bone Spine. 2011 Mar;78(2):188-93. doi: 10.1016/j.jbspin.2010.05.010.

PMID:
20621536
15.

Ocular Involvement Following an Epidemic of Toxoplasma gondii Infection in Santa Isabel do Ivaí, Brazil.

Silveira C, Muccioli C, Holland GN, Jones JL, Yu F, de Paulo A, Belfort R Jr.

Am J Ophthalmol. 2015 Jun;159(6):1013-1021.e3. doi: 10.1016/j.ajo.2015.02.017. Epub 2015 Mar 2.

PMID:
25743340
16.

No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months.

Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M.

Rheumatology (Oxford). 2013 Jan;52(1):204-9. doi: 10.1093/rheumatology/kes272. Epub 2012 Oct 13.

PMID:
23065359
17.

Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.

Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H.

Ann Rheum Dis. 2008 May;67(5):729-30. doi: 10.1136/ard.2007.077370. No abstract available.

PMID:
18408116
18.

Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis.

Lassoued S, Zabraniecki L, Marin F, Billey T.

Semin Arthritis Rheum. 2007 Feb;36(4):262-3. Epub 2006 Oct 25.

PMID:
17067660
19.

Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers.

Savastano M, Marioni G, Giacomelli L, Ramonda R, Ferraro SM, Punzi L.

B-ENT. 2010;6(3):183-8.

PMID:
21090160
20.

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.

Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL; BSR Biologics Register.

Rheumatology (Oxford). 2010 Mar;49(3):563-70. doi: 10.1093/rheumatology/kep422. Epub 2009 Dec 23.

Supplemental Content

Support Center